J. Jack Lee

List of Publications by Year
in descending order

488 papers	50,619 citations	1231 110 h-index	2027 205 g-index
512 all docs	512 docs citations	512 times ranked	48443 citing authors

#	Article	IF	Citations
1	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clinical Cancer Research, 2023, 27, 852-864.	3.2	61
2	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1327-1337.	0.4	29
3	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	1.1	2
4	TITEâ€BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with lateâ€onset toxicity and efficacy. Statistics in Medicine, 2022, 41, 1918-1931.	0.8	21
5	Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Localâ€“Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2022, 28, 1345-1352.	3.2	38
6	ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
7	A <scp>WIN</scp> Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced nonâ€small cell lung cancer. Cancer Medicine, 2022, 11, 2790-2800.	1.3	7
8	Bayesian Optimal Phase II Design for Randomized Clinical Trials. Statistics in Biopharmaceutical Research, 2022, 14, 423-432.	0.6	6
9	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	3.2	9
10	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	5.8	23
11	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , .	3.2	3
12	Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prevention Research, 2022, 15, 423-434.	0.7	1
13	Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival. Cancer Research Communications, 2022, 2, 590-601.	0.7	0
14	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589.	2.8	15
15	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut, 2021, 70, 555-566.	6.1	37
16	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer, 2021, 22, e415-e424.	1.1	10
17	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest, 2021, 159, 1256-1264.	0.4	14
18	A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3â€‰+â€‰3 (i3â€‰+â€‰3) Design for Phase I Oncology Dose-Finding Trials. Statistics in Biopharmaceutical Research, 2021, 13, 147-155.	0.6	3

#	Article	IF	Citations
19	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications, 2021, 12, 687.	5.8	30
20	BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clinical Cancer Informatics, 2021, 5, 91-101.	1.0	11
21	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	15.2	357
22	Evaluating Bayesian adaptive randomization procedures with adaptive clip methods for multi-arm trials. Statistical Methods in Medical Research, 2021, 30, 1273-1287.	0.7	3
23	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Advances in Radiation Oncology, 2021, 6, 100635.	0.6	3
24	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer, 2021, 127, 2916-2925.	2.0	5
25	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. Scientific Reports, 2021, 11, 8511.	1.6	24
26	Incorporating historical information to improve phase I clinical trials. Pharmaceutical Statistics, 2021, 20, 1017-1034.	0.7	12
27	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 601-609.	0.5	40
28	Immune evasion in HPV‹sup›â^'‹/sup›head and neck precancerâ€“cancer transition is driven by an aneuploid switch involving chromosome 9p loss. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	45
29	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nature Communications, 2021, 12, 2722.	5.8	74
30	The use of local and nonlocal priors in Bayesian testâ€based monitoring for singleâ€arm phase II clinical trials. Pharmaceutical Statistics, 2021, 20, 1183-1199.	0.7	2
31	IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Medical Research Methodology, 2021, 21, 111.	1.4	185
32	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	3.2	10
33	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A PhaseÂII Trial. Advances in Therapy, 2021, 38, 4581-4591.	1.3	7
34	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	3.2	8
35	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nature Communications, 2021, 12, 5045.	5.8	42
36	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107

#	Article	IF	Citations
37	Principles and Reporting of Bayesian Trials. Journal of Thoracic Oncology, 2021, 16, 30-36.	0.5	1
38	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
39	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	2.0	14
40	STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research, 2021, 27, 1720-1733.	3.2	44
41	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naÃ¯ve study. Genome Medicine, 2021, 13, 155.	3.6	44
42	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clinical and Research Reports, 2021, 2, 100237.	0.6	8
43	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. Npj Precision Oncology, 2021, 5, 94.	2.3	4
44	Inferential Frameworks for Clinical Trials. , 2021, , 1-30.		0
45	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	3.2	0
46	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	5.8	24
47	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	5.8	16
48	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	3.2	6
49	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	3.2	80
50	Response adaptive randomization procedures in seamless phase II/III clinical trials. Journal of Biopharmaceutical Statistics, 2020, 30, 3-17.	0.4	2
51	Borrowing strength and borrowing index for Bayesian hierarchical models. Computational Statistics and Data Analysis, 2020, 144, 106901.	0.7	7
52	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncology, 2020, 6, 375.	3.4	215
53	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2020, 101, 104523.	0.8	38
54	Statistical Methods in Precision Oncology. Journal of Clinical Oncology, 2020, 38, 660-661.	0.8	1

#	Article	IF	Citations
55	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	0.9	12
56	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
57	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clinical Cancer Research, 2020, 26, 5477-5486.	3.2	15
58	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	3.8	36
59	Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. Statistical Methods in Medical Research, 2020, 29, 2717-2732.	0.7	24
60	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist, 2020, 25, e1457-e1463.	1.9	7
61	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3525-3536.	3.2	22
62	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clinical Lung Cancer, 2020, 21, 341-348.	1.1	70
63	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1519-1534.	2.0	21
64	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clinical Lung Cancer, 2020, 21, 384-388.	1.1	11
65	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clinical Cancer Research, 2020, 26, 3211-3219.	3.2	64
66	Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. Emerging Topics in Statistics and Biostatistics, 2020, , 395-426.	0.1	3
67	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Annals of Thoracic Surgery, 2020, 110, 1131-1138.	0.7	8
68	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	0.5	109
69	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
70	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight, 2020, 5, .	2.3	130
71	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget, 2020, 11, 600-618.	0.8	15
72	Evaluation of bias for outcome adaptive randomization designs with binary endpoints. Statistics and Its Interface, 2020, 13, 287-315.	0.2	2

#	Article	IF	Citations
73	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 911-919.e6.	0.4	21
74	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	5.8	91
75	Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1521-1530.	0.6	94
76	Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 6383-6392.	1.3	10
77	A utilityâ€based Bayesian optimal interval (Uâ€BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Statistics in Medicine, 2019, 38, 5299-5316.	0.8	52
78	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clinical Trials, 2019, 16, 645-656.	0.7	11
79	Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. Biometrical Journal, 2019, 61, 1219-1231.	0.6	15
80	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. JNCI Cancer Spectrum, 2019, 3, pkz010.	1.4	8
81	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 2019, 37, 1558-1565.	0.8	882
82	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	0.5	79
83	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine, 2019, 25, 744-750.	15.2	443
84	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine, 2019, 25, 751-758.	15.2	362
85	Inference and Decision Making for 21st-Century Drug Development and Approval. American Statistician, 2019, 73, 319-327.	0.9	28
86	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. JCO Precision Oncology, 2019, 3, 1-14.	1.5	12
87	A Collection of Statistical Methods for Precision Oncology. JCO Precision Oncology, 2019, 3, 1-3.	1.5	0
88	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas, 2019, 48, 381-386.	0.5	8
89	Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precision Oncology, 2019, 3, 1-12.	1.5	31
90	Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Annals of Oncology, 2019, 30, 471-477.	0.6	17

#	Article	IF	Citations
91	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16â€“Related Cancer. JAMA Oncology, 2019, 5, 67.	3.4	344
92	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clinical Lung Cancer, 2019, 20, 30-36.e3.	1.1	37
93	Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.. Journal of Clinical Oncology, 2019, 37, 6008-6008.	0.8	17
94	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A singleâ€arm phase 2 clinical trial. Cancer, 2018, 124, 2169-2173.	2.0	86
95	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prevention Research, 2018, 11, 203-214.	0.7	17
96	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	2.9	56
97	Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist, 2018, 23, 526-e49.	1.9	15
98	Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. Journal of the National Cancer Institute, 2018, 110, 250-257.	3.0	17
99	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncology, 2018, 77, 92-97.	0.8	7
100	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 246-257.	0.5	14
101	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Nonâ€“Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology, 2018, 13, 779-791.	0.5	53
102	Controlled multi-arm platform design using predictive probability. Statistical Methods in Medical Research, 2018, 27, 65-78.	0.7	65
103	Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization. Journal of Biopharmaceutical Statistics, 2018, 28, 309-319.	0.4	7
104	Distinct pattern of TP53 mutations in human immunodeficiency virusâ€“related head and neck squamous cell carcinoma. Cancer, 2018, 124, 84-94.	2.0	22
105	Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint. Statistics in Biosciences, 2018, 10, 420-438.	0.6	7
106	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1813-1822.	0.8	243
107	PI3â€kinase pathway biomarkers in oral cancer and tumor immune cells. Head and Neck, 2018, 41, 615-622.	0.9	4
108	AACR White Paper: Shaping the Future of Cancer Prevention â€“ A Roadmap for Advancing Science and Public Health. Cancer Prevention Research, 2018, 11, 735-778.	0.7	36

#	Article	IF	Citations
109	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. Journal of Thoracic Oncology, 2018, 13, 1625-1637.	0.5	10
110	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	3.2	292
111	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
112	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	5.8	122
113	Effect of neoadjuvant chemotherapy on the immune microenvironment in nonâ€“small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
114	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26
115	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2018, 82, 83-90.	0.8	19
116	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget, 2018, 9, 33995-34008.	0.8	9
117	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clinical Cancer Research, 2017, 23, 1407-1413.	3.2	11
118	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clinical Cancer Research, 2017, 23, 1414-1421.	3.2	29
119	Monotonic single-index models to assess drug interactions. Statistics in Medicine, 2017, 36, 655-670.	0.8	2
120	Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. Journal of Clinical Oncology, 2017, 35, 352-360.	0.8	175
121	BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Statistics in Medicine, 2017, 36, 3302-3314.	0.8	62
122	Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature, 2017, 546, 498-503.	13.7	1,731
123	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1376-1387.	0.5	39
124	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 5489-5501.	3.2	55
125	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Molecular Cancer Research, 2017, 15, 179-188.	1.5	19
126	Prognostic biomarkers in patients with human immunodeficiency virusâ€positive disease with head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 2433-2443.	0.9	5

#	Article	IF	Citations
127	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	7.7	160
128	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 2234-2245.	1.9	72
129	A second-order semiparametric method for survival analysis, with application to an acquired immune deficiency syndrome clinical trial study. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 833-846.	0.5	0
130	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	51
131	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2017, 112, 90-95.	0.9	188
132	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	5.8	96
133	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	41
134	A robust twoâ€stage design identifying the optimal biological dose for phase I/II clinical trials. Statistics in Medicine, 2017, 36, 27-42.	0.8	25
135	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 2017, 28, 83-89.	0.6	97
136	Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression. Statistics in Biosciences, 2017, 9, 217-245.	0.6	8
137	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 770-777.	0.4	16
138	Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors. Journal of Adolescent and Young Adult Oncology, 2017, 6, 414-421.	0.7	16
139	Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9083-9083.	0.8	1
140	The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget, 2017, 8, 3-14.	0.8	52
141	Assessment of Drug Interactions with Repeated Measurements. ICSA Book Series in Statistics, 2017, , 277-291.	0.0	1
142	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer, 2016, 122, 534-545.	2.0	62
143	The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nature Communications, 2016, 7, 12961.	5.8	31
144	Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infectious Agents and Cancer, 2016, 11, 21.	1.2	14

#	Article	IF	Citations
145	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research, 2016, 76, 3690-3701.	0.4	203
146	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer â€“ A case matched analysis. Radiotherapy and Oncology, 2016, 120, 48-55.	0.3	177
147	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3638-3647.	0.8	140
148	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 2475-2485.	1.9	73
149	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	5.1	865
150	Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications, 2016, 7, 13200.	5.8	132
151	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms. JAMA Oncology, 2016, 2, 1452.	3.4	279
152	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology, 2016, 186, 2162-2170.	1.9	18
153	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment, 2016, 158, 67-77.	1.1	16
154	Image Analysisâ€“based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Nonâ€“small Cell Lung Carcinoma Patients. Clinical Cancer Research, 2016, 22, 6278-6289.	3.2	130
155	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	2.7	6
156	Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 585-601.	0.5	10
157	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.4	121
158	Response. Journal of the National Cancer Institute, 2016, 108, djw001.	3.0	0
159	Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Research, 2016, 76, 675-685.	0.4	84
160	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research, 2016, 9, 2-10.	0.7	130
161	Erlotinib and the Risk of Oral Cancer. JAMA Oncology, 2016, 2, 209.	3.4	111
162	Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences, 2016, 8, 99-128.	0.6	22

#	Article	IF	Citations
163	Calibrating the prior distribution for a normal model with conjugate prior. Journal of Statistical Computation and Simulation, 2015, 85, 3108-3128.	0.7	2
164	Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget, 2015, 6, 18707-18714.	0.8	52
165	drexplorer: A tool to explore doseâ€“response relationships and drugâ€“drug interactions. Bioinformatics, 2015, 31, 1692-1694.	1.8	22
166	Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 317-324.	0.4	59
167	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 2015, 26, 1476-1480.	0.6	71
168	Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 2015, 517, 576-582.	13.7	3,209
169	Phase II study of gefitinib in patients with advanced salivary gland cancers. Head and Neck, 2015, 37, 644-649.	0.9	85
170	CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: A tissue microarray study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015, 119, 553-565.	0.2	25
171	Testing hypotheses about medical test accuracy: considerations for design and inference. Journal of Applied Statistics, 2015, 42, 1106-1119.	0.6	0
172	Commentary on Hey and Kimmelman. Clinical Trials, 2015, 12, 110-112.	0.7	19
173	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Annals of Oncology, 2015, 26, 1791-1798.	0.6	68
174	Relationship Between Tumor Size and Survival in Nonâ€“Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal of Thoracic Oncology, 2015, 10, 682-690.	0.5	133
175	Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Molecular Cancer, 2015, 14, 113.	7.9	36
176	New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. Cancer Prevention Research, 2015, 8, 1027-1035.	0.7	60
177	Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung Cancer. Journal of Biological Chemistry, 2015, 290, 7345-7359.	1.6	36
178	Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2914-2919.	0.8	3
179	Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus. Cancer Prevention Research, 2015, 8, 1131-1137.	0.7	25
180	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. Journal of the National Cancer Institute, 2015, 107, djv253.	3.0	139

#	Article	IF	Citations
181	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of Clinical Oncology, 2015, 33, 3817-3825.	0.8	393
182	Simulation study for evaluating the performance of response-adaptive randomization. Contemporary Clinical Trials, 2015, 40, 15-25.	0.8	15
183	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. Journal of Clinical Oncology, 2015, 33, 11019-11019.	0.8	8
184	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	0.8	22
185	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget, 2015, 6, 16746-16756.	0.8	13
186	An overview of the design and conduct of the BATTLE trials. Chinese Clinical Oncology, 2015, 4, 33.	0.4	39
187	Cancer Chemoprevention. , 2015, , 809-824.e4.		0
188	Expression pattern of FGFR2, Grb2 and Plcî³1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. American Journal of Cancer Research, 2015, 5, 3135-48.	1.4	11
189	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics, 2014, 13, 3175-3184.	1.9	31
190	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 6582-6592.	3.2	493
191	Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs. Statistics in Medicine, 2014, 33, 4029-4042.	0.8	8
192	Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Annals of Oncology, 2014, 25, 1184-1192.	0.6	48
193	Adaptive Clinical Trials. Therapeutic Innovation and Regulatory Science, 2014, 48, 20-30.	0.8	16
194	Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials, 2014, 11, 319-327.	0.7	72
195	Prediction of Survival in Resected Nonâ€“Small Cell Lung Cancer Using a Protein Expressionâ€“Based Risk Model: Implications for Personalized Chemoprevention and Therapy. Clinical Cancer Research, 2014, 20, 1946-1954.	3.2	28
196	A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer. Oncologist, 2014, 19, 1040-1041.	1.9	37
197	Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage Iâ€“II Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 675-684.	0.5	22
198	VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2â€“Targeted Therapy. Clinical Cancer Research, 2014, 20, 3849-3861.	3.2	62

#	Article	IF	Citations
199	Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Reports, 2014, 6, 377-387.	2.9	210
200	Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 213-221.	1.1	22
201	Vandetanib and Indwelling Pleural Catheter for Nonâ€“Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. Clinical Lung Cancer, 2014, 15, 379-386.	1.1	13
202	One step forward, two steps back. Lancet Oncology, The, 2014, 15, 366-367.	5.1	8
203	Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Research, 2014, 74, 7181-7184.	0.4	53
204	Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. Carcinogenesis, 2014, 35, 1760-1764.	1.3	20
205	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 2014, 346, 256-259.	6.0	834
206	Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2014, 15, 197-201.	1.1	28
207	Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Annals of Diagnostic Pathology, 2014, 18, 140-145.	0.6	9
208	Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 603-610.	0.9	58
209	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	0.8	54
210	Adaptive clinical trial designs in oncology. Chinese Clinical Oncology, 2014, 3, .	0.4	10
211	ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 3383-3395.	3.2	146
212	RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials. Journal of the National Cancer Institute, 2013, 105, 833-833.	3.0	0
213	Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemporary Clinical Trials, 2013, 36, 642-650.	0.8	31
214	A Bayesian decisionâ€theoretic sequential responseâ€adaptive randomization design. Statistics in Medicine, 2013, 32, 1975-1994.	0.8	15
215	PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research, 2013, 73, 276-284.	0.4	262
216	Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 744-751.	0.8	271

#	Article	IF	Citations
217	Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method. Contemporary Clinical Trials, 2013, 35, 170-178.	0.8	3
218	An Epithelialâ€“Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	3.2	848
219	Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Nonâ€“Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling. Cancer Prevention Research, 2013, 6, 8-17.	0.7	36
220	CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma. Cancer Research, 2013, 73, 571-582.	0.4	138
221	Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease. Molecular Cancer Therapeutics, 2013, 12, 1112-1121.	1.9	34
222	Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?. Clinical Cancer Research, 2013, 19, 4305-4308.	3.2	8
223	Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial. Clinical Cancer Research, 2013, 19, 6967-6975.	3.2	57
224	EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Nonâ€“Small Cell Lung Carcinoma. Clinical Cancer Research, 2013, 19, 6556-6565.	3.2	124
225	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Molecular Cancer Therapeutics, 2013, 12, 2857-2863.	1.9	42
226	Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer, 2013, 119, 4277-4283.	2.0	32
227	Reply to A. Levy et al. Journal of Clinical Oncology, 2013, 31, 396-396.	0.8	4
228	Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial. Journal of Thoracic Oncology, 2013, 8, 658-661.	0.5	19
229	Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Nonâ€“Small-Cell Lung Cancer after Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2013, 8, 222-228.	0.5	104
230	Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial. Journal of Thoracic Oncology, 2013, 8, 436-442.	0.5	82
231	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, TPS8118-TPS8118.	0.8	4
232	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget, 2013, 4, 705-714.	0.8	96
233	Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Journal of the National Cancer Institute, 2012, 104, 228-239.	3.0	424
234	Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization. Clinical Cancer Research, 2012, 18, 4498-4507.	3.2	56

#	Article	IF	Citations
235	Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention. Clinical Cancer Research, 2012, 18, 3705-3713.	3.2	49
236	Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies. Journal of Clinical Oncology, 2012, 30, 2684-2690.	0.8	86
237	The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Annals of Oncology, 2012, 23, 78-85.	0.6	57
238	Tissue Platinum Concentration and Tumor Response in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3345-3352.	0.8	81
239	Loss of Heterozygosity (LOH) Profilesâ€”Validated Risk Predictors for Progression to Oral Cancer. Cancer Prevention Research, 2012, 5, 1081-1089.	0.7	165
240	g-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1747-1754.	0.5	51
241	Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2012, 7, 825-832.	0.5	280
242	Accuracy of In Vivo Multimodal Optical Imaging for Detection of Oral Neoplasia. Cancer Prevention Research, 2012, 5, 801-809.	0.7	92
243	Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial. Journal of Thoracic Oncology, 2012, 7, 1645-1652.	0.5	21
244	High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. Journal of Thoracic Oncology, 2012, 7, 833-840.	0.5	123
245	Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. International Journal of Oncology, 2012, 41, 1798-1808.	1.4	11
246	Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-Based System to Support Clinical Trialsâ€”Report of the NationalÂCancer Institute Work Group on Radiotherapy Quality Assurance. International Journal of Radiation Oncology Biology Physics, 2012, 83, 782-790.	0.4	62
247	Influence of Chemotherapy on EGFR Mutation Status Among Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3077-3083.	0.8	188
248	Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans. PLoS ONE, 2012, 7, e34833.	1.1	149
249	Bayesian clinical trials in action. Statistics in Medicine, 2012, 31, 2955-2972.	0.8	131
250	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology, 2012, 30, 777-782.	0.8	414
251	Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer, 2012, 118, 2454-2465.	2.0	57
252	Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer, 2012, 118, 2889-2899.	2.0	91

#	Article	IF	Citations
253	Epidermal growth factor receptor and Kâ€Ras mutations and resistance of lung cancer to insulinâ€like growth factor 1 receptor tyrosine kinase inhibitors. Cancer, 2012, 118, 3993-4003.	2.0	39
254	Phase II Trial Design with Bayesian Adaptive Randomization and Predictive Probability. Journal of the Royal Statistical Society Series C: Applied Statistics, 2012, 61, 219-235.	0.5	57
255	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget, 2012, 3, 1566-1575.	0.8	79
256	The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011, 1, 44-53.	7.7	778
257	The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration. Cancer Prevention Research, 2011, 4, 962-972.	0.7	47
258	Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells. PLoS ONE, 2011, 6, e21428.	1.1	77
259	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769.	1.1	174
260	Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients. Cancer Prevention Research, 2011, 4, 185-193.	0.7	36
261	Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2011, 6, 2104-2111.	0.5	26
262	Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. Experimental and Therapeutic Medicine, 2011, 2, 137-142.	0.8	3
263	KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene, 2011, 30, 3163-3173.	2.6	31
264	Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. BMC Cancer, 2011, 11, 462.	1.1	36
265	Immunohistochemical Overexpression of Platelet-Derived Growth Factor Receptorâ€“Beta (PDGFR-Î²) is Associated With PDGFRB Gene Copy Number Gain in Sarcomatoid Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2011, 12, 369-374.	1.1	34
266	Differential Impacts of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) in Epithelial IGF-Induced Lung Cancer Development. Endocrinology, 2011, 152, 2164-2173.	1.4	20
267	Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy. Cancer Prevention Research, 2011, 4, 779-782.	0.7	15
268	Rebuttal to the Response of Chou. Cancer Research, 2011, 71, 2798-2800.	0.4	2
269	Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis. Clinical Cancer Research, 2011, 17, 2434-2443.	3.2	74
270	Demystify Statistical Significance--Time to Move on From the P Value to Bayesian Analysis. Journal of the National Cancer Institute, 2011, 103, 2-3.	3.0	27

#	Article	IF	Citations
271	A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis. Clinical Cancer Research, 2011, 17, 1490-1501.	3.2	63
272	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activityâ€"Response. Cancer Research, 2011, 71, 2794-2795.	0.4	3
273	A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer. Cancer Prevention Research, 2011, 4, 1580-1589.	0.7	46
274	Gene Expression Profiling Predicts the Development of Oral Cancer. Cancer Prevention Research, 2011, 4, 218-229.	0.7	121
275	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer Research, 2011, 17, 2035-2043.	3.2	81
276	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Nonâ€"Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research, 2011, 71, 5512-5521.	0.4	55
277	Phase II Trials with Anticancer Agents. , 2011, , 141-161.		0
278	A simulation study for comparing testing statistics in response-adaptive randomization. BMC Medical Research Methodology, 2010, 10, 48.	1.4	12
279	Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmallâ€cell lung cancer. Cancer, 2010, 116, 2401-2408.	2.0	17
280	Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Molecular Carcinogenesis, 2010, 49, 183-189.	1.3	90
281	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 667-674.	0.4	21
282	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1Î± in non-small cell lung cancer cells. Oncogene, 2010, 29, 2616-2627.	2.6	87
283	CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation, 2010, 45, 498-504.	1.3	46
284	Emax model and interaction index for assessing drug interaction in combination studies. Frontiers in Bioscience - Elite, 2010, E2, 582-601.	0.9	5
285	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. Journal of Clinical Oncology, 2010, 28, 8-14.	0.8	234
286	Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers. Cancer Prevention Research, 2010, 3, 148-159.	0.7	50
287	Expression of Interleukin-1 Receptorâ€"Associated Kinase-1 in Nonâ€"Small Cell Lung Carcinoma and Preneoplastic Lesions. Clinical Cancer Research, 2010, 16, 34-44.	3.2	33
288	Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse. Clinical Cancer Research, 2010, 16, 1289-1297.	3.2	114

#	Article	IF	Citations
289	MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis, 2010, 31, 2118-2123.	1.3	52
290	Validation of a Novel Statistical Model for Assessing the Synergy of Combined-Agent Cancer Chemoprevention. Cancer Prevention Research, 2010, 3, 917-928.	0.7	2
291	Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis, 2010, 31, 1755-1761.	1.3	20
292	Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer. Molecular Cancer Therapeutics, 2010, 9, 1755-1763.	1.9	43
293	Bayesian adaptive randomization designs for targeted agent development. Clinical Trials, 2010, 7, 584-596.	0.7	95
294	Mortality in the Randomized, Controlled Lung Intergroup Trial of Isotretinoin. Cancer Prevention Research, 2010, 3, 738-744.	0.7	10
295	Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 193-201.	0.8	131
296	Chemoradiotherapy With or Without AE-941 in Stage III Nonâ€“Small Cell Lung Cancer: A Randomized Phase III Trial. Journal of the National Cancer Institute, 2010, 102, 859-865.	3.0	64
297	Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of Oral Cancer. Cancer Prevention Research, 2010, 3, 800-809.	0.7	108
298	Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. Journal of Biomedical Optics, 2010, 15, 066017.	1.4	23
299	Applying Emax model and bivariate thin plate splines to assess drug interactions. Frontiers in Bioscience - Elite, 2010, E2, 279-292.	0.9	3
300	Abstract 787: Differences in protein expression patterns in lung adenocarcinomas arising in never versus ever smokers. , 2010, , .		1
301	Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Nonâ€“Small-Cell Lung Cancer as Frontline and Second-Line Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 148-152.	0.6	10
302	A Systems Biology-Based Gene Expression Classifier of Glioblastoma Predicts Survival with Solid Tumors. PLoS ONE, 2009, 4, e6274.	1.1	19
303	Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients. Cancer Prevention Research, 2009, 2, 14-21.	0.7	42
304	Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using anIn vitroLung Carcinogenesis System. Cancer Prevention Research, 2009, 2, 702-711.	0.7	56
305	Î”Np63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia. Clinical Cancer Research, 2009, 15, 6284-6291.	3.2	61
306	Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer. Journal of Clinical Oncology, 2009, 27, 1976-1982.	0.8	47

#	Article	IF	Citations
307	Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Chest, 2009, 136, 701-709.	0.4	105
308	Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. Statistics in Biopharmaceutical Research, 2009, 1, 4-17.	0.6	36
309	Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation. Clinical Cancer Research, 2009, 15, 5359-5368.	3.2	150
310	Randomized Trial of 13-cis Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral Premalignancy. Journal of Clinical Oncology, 2009, 27, 599-604.	0.8	96
311	Elevated Epithelial Insulin-like Growth Factor Expression Is a Risk Factor for Lung Cancer Development. Cancer Research, 2009, 69, 7439-7448.	0.4	60
312	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials, 2009, 6, 205-216.	0.7	106
313	Objective Detection and Delineation of Oral Neoplasia Using Autofluorescence Imaging. Cancer Prevention Research, 2009, 2, 423-431.	0.7	158
314	Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions. Cancer Prevention Research, 2009, 2, 931-941.	0.7	210
315	Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells. Technology in Cancer Research and Treatment, 2009, 8, 163-175.	0.8	4
316	High-Dose Fenretinide in Oral Leukoplakia. Cancer Prevention Research, 2009, 2, 22-26.	0.7	42
317	Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants. Cancer Prevention Research, 2009, 2, 617-624.	0.7	55
318	Response: Re: Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute, 2009, 101, 1733-1735.	3.0	2
319	A phase 2 study of cetuximab in combination with docetaxel in chemotherapyâ€refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer, 2009, 115, 1713-1722.	2.0	35
320	Cyclooxygenaseâ€2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer, 2009, 115, 1498-1506.	2.0	22
321	Noninvasive evaluation of oral lesions using depthâ€sensitive optical spectroscopy. Cancer, 2009, 115, 1669-1679.	2.0	102
322	Comparison of Bayesian sample size criteria: ACC, ALC, and WOC. Journal of Statistical Planning and Inference, 2009, 139, 4111-4122.	0.4	20
323	Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C. Annals of Surgical Oncology, 2009, 16, 2181-2187.	0.7	64
324	Prospective Risk-Adjusted [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 2509-2515.	0.8	156

#	Article	IF	Citations
325	Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute, 2009, 101, 708-720.	3.0	678
326	Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 15-19.	0.6	4
327	Costâ€effectiveness of prostate cancer chemoprevention. Cancer, 2008, 112, 1058-1065.	2.0	61
328	Genetic variations in cellâ€cycle pathway and the risk of oral premalignant lesions. Cancer, 2008, 113, 2488-2495.	2.0	21
329	A predictive probability design for phase II cancer clinical trials. Clinical Trials, 2008, 5, 93-106.	0.7	140
330	A Semiparametric Response Surface Model for Assessing Drug Interaction. Biometrics, 2008, 64, 396-405.	0.8	28
331	Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. European Journal of Cancer, 2008, 44, 1603-1611.	1.3	27
332	Podoplanin: A Novel Marker for Oral Cancer Risk in Patients With Oral Premalignancy. Journal of Clinical Oncology, 2008, 26, 354-360.	0.8	184
333	Model diagnostic tests for selecting informative correlation structure in correlated data. Biometrika, 2008, 95, 891-905.	1.3	5
334	Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions. Clinical Cancer Research, 2008, 14, 2095-2101.	3.2	94
335	Impact of Smoking Cessation on Global Gene Expression in the Bronchial Epithelium of Chronic Smokers. Cancer Prevention Research, 2008, 1, 112-118.	0.7	65
336	Oral Epithelium as a Surrogate Tissue for Assessing Smoking-Induced Molecular Alterations in the Lungs. Cancer Prevention Research, 2008, 1, 39-44.	0.7	76
337	Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer. Clinical Cancer Research, 2008, 14, 6014-6022.	3.2	104
338	Bayesian adaptive design for targeted therapy development in lung cancer â€" a step toward personalized medicine. Clinical Trials, 2008, 5, 181-193.	0.7	199
339	Cancer Chemoprevention. , 2008, , 711-720.		1
340	Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer. Journal of Clinical Oncology, 2007, 25, 2164-2170.	0.8	356
341	Randomized Trial of Adjuvant 13-cis-Retinoic Acid and Interferon Alfa for Patients With Aggressive Skin Squamous Cell Carcinoma. Journal of Clinical Oncology, 2007, 25, 1974-1978.	0.8	80
342	Identification of the Retinoic Acid-Inducible Gprc5a As a New Lung Tumor Suppressor Gene. Journal of the National Cancer Institute, 2007, 99, 1668-1682.	3.0	104

#	Article	IF	Citations
343	Proliferative Changes in the Bronchial Epithelium of Former Smokers Treated With Retinoids. Journal of the National Cancer Institute, 2007, 99, 1603-1612.	3.0	18
344	Repair Capacity for UV Lightâ€“Induced DNA Damage Associated with Risk of Nonmelanoma Skin Cancer and Tumor Progression. Clinical Cancer Research, 2007, 13, 6532-6539.	3.2	44
345	Nucleotide Excision Repair Pathway Genes and Oral Premalignant Lesions. Clinical Cancer Research, 2007, 13, 3753-3758.	3.2	55
346	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Molecular Cancer Therapeutics, 2007, 6, 1962-1972.	1.9	118
347	Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy. Journal of Biopharmaceutical Statistics, 2007, 17, 461-480.	0.4	123
348	The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Letters, 2006, 239, 136-143.	3.2	37
349	A Generalized Response Surface Model with Varying Relative Potency for Assessing Drug Interaction. Biometrics, 2006, 62, 986-995.	0.8	53
350	Asian Ethnicity as a Predictor of Response in Patients with Nonâ€“Small-Cell Lung Cancer Treated with Gefitinib on an Expanded Access Program. Clinical Lung Cancer, 2006, 7, 326-331.	1.1	27
351	Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer, 2006, 106, 2428-2436.	2.0	152
352	Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer, 2006, 107, 563-569.	2.0	276
353	Nuclear factor-ÎºB (nf-ÎºB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer, 2006, 107, 2637-2646.	2.0	179
354	Randomized Phase III Trial of Low-dose Isotretinoin for Prevention of Second Primary Tumors in Stage I and II Head and Neck Cancer Patients. Journal of the National Cancer Institute, 2006, 98, 441-450.	3.0	226
355	Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis, 2006, 27, 2034-2037.	1.3	44
356	Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancerâ€”A Plan to Move Forward. Clinical Cancer Research, 2006, 12, 3661-3697.	3.2	263
357	Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck. Journal of Clinical Oncology, 2006, 24, 4163-4169.	0.8	59
358	Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study. Clinical Cancer Research, 2006, 12, 2178-2184.	3.2	47
359	Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia. Clinical Cancer Research, 2006, 12, 3109-3114.	3.2	48
360	Reducing the â€œRiskâ€•of Chemoprevention: Defining and Targeting High Riskâ€”2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Research, 2006, 66, 2893-2903.	0.4	39

#	Article	IF	Citations
361	Identification and Validation of Differences in Protein Levels in Normal, Premalignant, and Malignant Lung Cells and Tissues Using High-Throughput Western Array and Immunohistochemistry. Cancer Research, 2006, 66, 11194-11206.	0.4	49
362	The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1485-1489.	1.1	30
363	Expression of Î”DNMT3B Variants and Its Association with Promoter Methylation of p16 and RASSF1A in Primary Nonâ€“Small Cell Lung Cancer. Cancer Research, 2006, 66, 8361-8366.	0.4	62
364	Decision Analysis for Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 3597-3603.	0.8	75
365	Lymph Node Metastases from Cutaneous Squamous Cell Carcinoma of the Head and Neck. Laryngoscope, 2005, 115, 1561-1567.	1.1	261
366	Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer, 2005, 103, 952-959.	2.0	26
367	Akt activation correlates with adverse outcome in tongue cancer. Cancer, 2005, 104, 2430-2436.	2.0	110
368	A weight-adjusted Peto?s test when cause of death is not assigned. Environmental and Ecological Statistics, 2005, 12, 95-113.	1.9	0
369	Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes. Journal of Clinical Oncology, 2005, 23, 1911-1920.	0.8	33
370	Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 2544-2555.	0.8	545
371	9-cis-Retinoic Acid Treatment Increases Serum Concentrations of Î±-Tocopherol in Former Smokers. Clinical Cancer Research, 2005, 11, 2305-2311.	3.2	5
372	Increased Retinoic Acid Receptor-Â4 Correlates In vivo with Reduced Retinoic Acid Receptor-Â2 in Esophageal Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 826-829.	1.1	24
373	Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers. Journal of Clinical Oncology, 2005, 23, 4439-4449.	0.8	10
374	Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions. Journal of Clinical Oncology, 2005, 23, 4450-4457.	0.8	124
375	Aurora- A/STK15 T + 91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis, 2005, 26, 1368-1373.	1.3	132
376	Mortality Risk From Squamous Cell Skin Cancer. Journal of Clinical Oncology, 2005, 23, 759-765.	0.8	384
377	Hypermethylation of the Retinoic Acid Receptor-Î²2 Gene in Head and Neck Carcinogenesis. Clinical Cancer Research, 2004, 10, 1733-1742.	3.2	124
378	Loss of Fhit Expression in Head and Neck Squamous Cell Carcinoma and Its Potential Clinical Implication. Clinical Cancer Research, 2004, 10, 5554-5557.	3.2	20

#	Article	IF	Citations
379	Tetranucleotide Microsatellite Instability in Surgical Margins for Prediction of Local Recurrence of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2004, 10, 4022-4028.	3.2	33
380	Expression of Hepatoma-Derived Growth Factor Is a Strong Prognostic Predictor for Patients With Early-Stage Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 3230-3237.	0.8	109
381	The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. New England Journal of Medicine, 2004, 350, 1405-1413.	13.9	99
382	Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 6119-6125.	3.2	84
383	Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer, 2004, 101, 2837-2842.	2.0	120
384	Gene Expression Screening of Salivary Gland Neoplasms. Journal of Molecular Diagnostics, 2004, 6, 180-190.	1.2	44
385	Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes and Control, 2003, 14, 131-138.	0.8	140
386	Phase I Study of Weekly Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 5, 40-45.	1.1	5
387	Estimation ofk for the poly-k test with application to animal carcinogenicity studies. Statistics in Medicine, 2003, 22, 2619-2636.	0.8	9
388	A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer, 2003, 39, 55-61.	0.9	190
389	The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Annals of Thoracic Surgery, 2003, 76, 1001-1008.	0.7	117
390	Retinoic Acid Receptor Â and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers. Journal of the National Cancer Institute, 2003, 95, 165-168.	3.0	20
391	Cyclin D1 Genotype, Response to Biochemoprevention, and Progression Rate to Upper Aerodigestive Tract Cancer. Journal of the National Cancer Institute, 2003, 95, 198-205.	3.0	93
392	Treatment of Former Smokers With 9-cis-Retinoic Acid Reverses Loss of Retinoic Acid Receptor-Â Expression in the Bronchial Epithelium: Results From a Randomized Placebo-Controlled Trial. Journal of the National Cancer Institute, 2003, 95, 206-214.	3.0	86
393	Statistical Methods for Biomarker Analysis for Head and Neck Carcinogenesis and Prevention. , 2003, , 287-IV.		0
394	Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clinical Cancer Research, 2003, 9, 93-101.	3.2	166
395	Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clinical Cancer Research, 2003, 9, 2400-5.	3.2	20
396	Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial. Journal of Clinical Oncology, 2002, 20, 2045-2052.	0.8	358

#	Article	IF	Citations
397	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. Journal of Clinical Oncology, 2002, 20, 364-370.	0.8	72
398	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. Journal of Clinical Oncology, 2002, 20, 364-370.	0.8	129
399	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer, 2002, 95, 340-353.	2.0	34
400	Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene, 2002, 21, 8206-8219.	2.6	44
401	Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1097-1105.	0.4	1,294
402	A Web-Based Simulator for Sample Size and Power Estimation in Animal Carcinogenicity Studies. Journal of Statistical Software, 2002, 7, .	1.8	4
403	Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Research, 2002, 62, 351-5.	0.4	103
404	GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Research, 2002, 62, 1178-83.	0.4	39
405	Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Research, 2002, 62, 2813-8.	0.4	36
406	Design considerations for efficient prostate cancer chemoprevention trials. Urology, 2001, 57, 205-212.	0.5	19
407	Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog. Journal of Clinical Oncology, 2001, 19, 1493-1500.	0.8	34
408	Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer, 2001, 91, 1316-1323.	2.0	70
409	Uniform Power Method for Sample Size Calculation in Historical Control Studies with Binary Response. Contemporary Clinical Trials, 2001, 22, 390-400.	2.0	14
410	Î²-carotene may not prevent second head and neck cancer. Evidence-based Oncology, 2001, 2, 200-201.	0.1	0
411	Effects of N-(4-Hydroxyphenyl)retinamide on hTERT Expression in the Bronchial Epithelium of Cigarette Smokers. Journal of the National Cancer Institute, 2001, 93, 1257-1263.	3.0	56
412	Long-Term Impact of Smoking on Lung Epithelial Proliferation in Current and Former Smokers. Journal of the National Cancer Institute, 2001, 93, 1081-1088.	3.0	87
413	Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2001, 93, 605-618.	3.0	295
414	Preliminary Results of a Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy With 78 Gy for Prostate Cancer. Journal of Clinical Oncology, 2000, 18, 3904-3911.	0.8	479

#	Article	IF	Citations
415	Extensions and Applications of Event Charts. American Statistician, 2000, 54, 63.	0.9	8
416	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). Cancer Gene Therapy, 2000, 7, 530-536.	2.2	63
417	Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2000, 18, 609-609.	0.8	328
418	Retinoic Acid Receptor-Beta as a Prognostic Indicator in Stage I Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2000, 18, 2798-2804.	0.8	86
419	15-LOX-1: a Novel Molecular Target of Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells. Journal of the National Cancer Institute, 2000, 92, 1136-1142.	3.0	143
420	Extensions and Applications of Event Charts. American Statistician, 2000, 54, 63-70.	0.9	16
421	Hypermethylation of the Death-Associated Protein (DAP) Kinase Promoter and Aggressiveness in Stage I Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2000, 92, 1511-1516.	3.0	265
422	Biochemopreventive Therapy for Patients With Premalignant Lesions of the Head and Neck and p53 Gene Expression. Journal of the National Cancer Institute, 2000, 92, 69-73.	3.0	43
423	Predicting cancer development in oral leukoplakia: ten years of translational research. Clinical Cancer Research, 2000, 6, 1702-10.	3.2	313
424	Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients. Journal of Clinical Oncology, 1999, 17, 976-976.	0.8	1,166
425	Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 1999, 91, 763-771.	3.0	473
426	Re: Cancer Chemoprevention: Progress and Promise Â RESPONSE. Journal of the National Cancer Institute, 1999, 91, 563-565.	3.0	5
427	Nuclear Retinoid Acid Receptor Beta in Bronchial Epithelium of Smokers Before and During Chemoprevention. Journal of the National Cancer Institute, 1999, 91, 1317-1321.	3.0	73
428	Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urological Research, 1999, 27, 362-367.	1.5	54
429	A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer, 1999, 86, 2291-2300.	2.0	4
430	Accrual strategies for phase I trials with delayed patient outcome. , 1999, 18, 1155-1169.		54
431	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery, 1998, 124, 203-210.	1.0	188
432	Nonparametric Regression Analysis of Longitudinal Data. Journal of the American Statistical Association, 1998, 93, 1403-1418.	1.8	129

#	Article	IF	Citations
433	Benzo[a]pyrene Diol Epoxide and Bleomycin Sensitivity and Susceptibility to Cancer of Upper Aerodigestive Tract. Journal of the National Cancer Institute, 1998, 90, 1393-1399.	3.0	62
434	Mutagen Sensitivity as aPredictor of Tumor Recurrence in Patients With Cancer of the Upper Aerodigestive Tract. Journal of the National Cancer Institute, 1998, 90, 243-245.	3.0	36
435	Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy. Journal of the National Cancer Institute, 1998, 90, 1545-1551.	3.0	135
436	Cancer Chemoprevention: Progress and Promise. Journal of the National Cancer Institute, 1998, 90, 1514-1528.	3.0	145
437	Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. Carcinogenesis, 1998, 19, 93-98.	1.3	15
438	Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Research, 1998, 8, 549-556.	0.6	72
439	DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Research, 1998, 8, 145-148.	0.6	3
440	Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Research, 1998, 8, 149-155.	0.6	13
441	Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.. Journal of Clinical Oncology, 1998, 16, 2253-2260.	0.8	546
442	Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 1998, 16, 1325-1330.	0.8	104
443	Suppression of Retinoic Acid Receptor Â in Non-Small-Cell Lung Cancer In Vivo: Implications for Lung Cancer Development. Journal of the National Cancer Institute, 1997, 89, 624-629.	3.0	176
444	Clonal Genetic Alterations in the Lungs of Current and Former Smokers. Journal of the National Cancer Institute, 1997, 89, 857-862.	3.0	385
445	Low-Dose Isotretinoin Versus Â-Carotene to Prevent Oral Carcinogenesis: Long-term Follow-up. Journal of the National Cancer Institute, 1997, 89, 257-258.	3.0	87
446	Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Annals of Oncology, 1997, 8, 85-89.	0.6	42
447	A Versatile One-Dimensional Distribution Plot: The BLiP Plot. American Statistician, 1997, 51, 353-358.	0.9	10
448	Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients.. Journal of Clinical Oncology, 1997, 15, 2826-2831.	0.8	84
449	Likelihood-Weighted Confidence Intervals for the Difference of Two Binomial Proportions. Biometrical Journal, 1997, 39, 387-407.	0.6	11
450	Polyamine measurements in the uterine cervix. Journal of Cellular Biochemistry, 1997, 67, 125-132.	1.2	10

#	Article	IF	Citations
451	Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. Gastroenterology, 1996, 111, 1493-1500.	0.6	11
452	Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.. Journal of Clinical Oncology, 1996, 14, 503-513.	0.8	104
453	Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.. Journal of Clinical Oncology, 1996, 14, 287-295.	0.8	93
454	Calcium carbonate treatment of diarrhoea in intestinal bypass patients. European Journal of Gastroenterology and Hepatology, 1996, 8, 559-562.	0.8	4
455	Retrovirusâ€“mediated wildâ€“type P53 gene transfer to tumors of patients with lung cancer.. Nature Medicine, 1996, 2, 985-991.	15.2	689
456	p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute, 1996, 88, 519-529.	3.0	171
457	Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.. Journal of Clinical Oncology, 1995, 13, 1893-1903.	0.8	151
458	Prognostic value of size of lymph node metastases in patients with cutaneous melanoma.. Journal of Clinical Oncology, 1995, 13, 2361-2368.	0.8	89
459	Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Annals of Thoracic Surgery, 1995, 60, 1563-1572.	0.7	193
460	Suppression of Retinoic Acid Receptorâ€“Î² in Premalignant Oral Lesions and Its Up-Regulation by Isotretinoin. New England Journal of Medicine, 1995, 332, 1405-1411.	13.9	377
461	p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Research, 1995, 55, 16-9.	0.4	138
462	Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia.. Journal of Clinical Oncology, 1994, 12, 937-945.	0.8	172
463	Quality of life in adult survivors of lung, colon and prostate cancer. Quality of Life Research, 1994, 3, 127-141.	1.5	306
464	Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, dna ploidy, and disease relapse. Cancer, 1994, 74, 2908-2917.	2.0	48
465	Micronuclei, a biomarker for chemoprevention trials: Results of a randomized study in oral pre-malignancy. International Journal of Cancer, 1994, 59, 457-459.	2.3	36
466	A Better Confidence Interval for Kappa (Îº) on Measuring Agreement between Two Raters with Binary Outcomes. Journal of Computational and Graphical Statistics, 1994, 3, 301-321.	0.9	24
467	Surgical treatment of multiple brain metastases. Journal of Neurosurgery, 1993, 79, 210-216.	0.9	487
468	On Recensoring for Censored Paired Data. Journal of the American Statistical Association, 1993, 88, 104.	1.8	2

#	Article	IF	Citations
469	Anticlastogenic effects of 13-cis-retinoic acid in vitro. European Journal of Cancer, 1993, 29, 137-140.	1.3	12
470	Comparison of Low-Dose Isotretinoin with Beta Carotene to Prevent Oral Carcinogenesis. New England Journal of Medicine, 1993, 328, 15-20.	13.9	368
471	On Recensoring for Censored Paired Data. Journal of the American Statistical Association, 1993, 88, 104-118.	1.8	3
472	Exploring the influence of multiple variables on the relationship of age to quality of life in women WITH BREAST CANCER. Journal of Clinical Epidemiology, 1992, 45, 473-485.	2.4	94
473	The incidence of second primary tumors in long-term survivors of small-cell lung cancer.. Journal of Clinical Oncology, 1992, 10, 1519-1524.	0.8	82
474	The CARES: a generic measure of health-related quality of life for patients with cancer. Quality of Life Research, 1992, 1, 19-29.	1.5	233
475	Breast conservationversus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. Cancer, 1992, 69, 1729-1738.	2.0	303
476	Jaw pain and tenderness levels during and after repeated sustained maximum voluntary protrusion. Pain, 1991, 45, 17-22.	2.0	25
477	Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 1991, 67, 3131-3135.	2.0	331
478	Percutaneous nephrostomy tube placement: an outpatient procedure?. Radiology, 1991, 179, 843-847.	3.6	52
479	A Note on the Conditional Approach to Interval Estimation in the Calibration Problem. Biometrics, 1991, 47, 1573.	0.8	7
480	Antibiotic prophylaxis for Dental Patients with Joint Prostheses? A Decision Analysis. International Journal of Technology Assessment in Health Care, 1990, 6, 569-587.	0.2	27
481	Second trimester maternal serum pregnancy specific beta-1 glycoprotein (SP-1) levels in normal and down syndrome pregnancies. American Journal of Medical Genetics Part A, 1990, 37, 114-118.	2.4	18
482	Jaw Pain and Stiffness Levels After Repeated Maximum Voluntary Clenching. Journal of Dental Research, 1989, 68, 69-71.	2.5	39
483	Electronic thermography of normal facial structures: A pilot study. Oral Surgery, Oral Medicine, and Oral Pathology, 1989, 68, 346-351.	0.6	23
484	A note on confidence limits for quartiles with right censored data. Statistics in Medicine, 1989, 8, 1269-1276.	0.8	11
485	Evaluation of lopamidol and diatrizoate in excretory urography: a double-blind clinical study. American Journal of Roentgenology, 1988, 151, 523-527.	1.0	12
486	The effective use of a local area network for the data management of clinical and nutritional data from a multicenter clinical trial. Contemporary Clinical Trials, 1986, 7, 234.	2.0	0

#	Article	IF	Citations
487	Simultaneous non-parametric confidence intervals for survival probabilities from censored data. Statistics in Medicine, 1986, 5, 653-662.	0.8	11
488	Bayesian Adaptive Methods for Clinical Trials. , 0, , .		270